MYND Life Sciences Inc. Has Management CTO Revoked
MYND Life Sciences Inc. Has Management CTO Revoked
Vancouver, British Columbia--(Newsfile Corp. - May 9, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological diseases, today announced details regarding its Management Cease Trade Order.
溫哥華，不列顛哥倫比亞省-(Newsfile Corp.-2023年5月9日)-MyND生命科學(CSE：MyND)(OTCQB：MYNDF)(“我的名字“或”公司“)，一家為患有無情的神經疾病的患者創造創新精確藥物的生物製藥研發公司，今天宣佈了其管理停止交易令的細節。
In accordance with the alternative information guidelines set out in National Policy 12-203 – Management Cease Trade Orders ("NP 12-203") MYND is giving the following update:
On March 1, 2023, the Company announced that it applied for a management cease trade order ("MCTO") with the applicable securities regulatory authorities in Canada on the basis that the Company would be unable to file its Annual Audited Financial Statement, the Required Filing, for the year ended October 31, 2022 by the applicable filing deadlines. The MCTO was issued on March 1, 2023 and restricted all trading in securities of the Company, whether direct or indirect, by the Chief Executive Officer and Chief Financial Officer of the Company.
根據國家政策12-203中規定的替代資訊指南--管理層停止交易令(“NP 12-203”)MyND提供以下更新：
於2023年3月1日，本公司宣佈已向加拿大適用的證券監管當局申請管理停止交易令(“MCTO”)，理由是本公司將無法在適用的提交截止日期前提交其截至2022年10月31日止年度的經審核年度財務報表。MCTO於2023年3月1日發出，限制公司首席執行官和首席財務官進行的所有證券交易，無論是直接的還是間接的。
Mynd is pleased to announce that under section 164 of the Securities Act the MCTO has been revoked upon the filing of all necessary documentation including the Annual Audited Financial Statements and Q1 Financial Statements. Mynd is now up to date on all filings.
MyND高興地宣佈，根據證券法第164條，一旦提交了所有必要的檔案，包括年度審計財務報表和第一季度財務報表，MCTO已被撤銷。MyND現在是所有檔案的最新版本。
The Company would like to thank all management for their diligence in achieving this timeline.
本公司感謝所有管理層為實現這一時間表所付出的辛勤努力。
ABOUT MYND LIFE SCIENCES INC.
關於MyND生命科學公司。
MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel drug development, diagnostics and vaccines. MYND is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by unique molecular concepts for the applications of psilocybin analogs for overcoming disease. The Company advances pharmaceutical developments through rigorous science and clinical trials while diligently patenting and safeguarding its intellectual property.
我的名字生命科學公司是一家專注於神經藥物和新藥開發、診斷和疫苗的醫用生物技術藥物研究和開發公司。我的名字正在開發新的生物實體(NBE)和新的化學實體(NCE)，並通過獨特的分子概念將自己與其他(生物)製藥公司區分開來，應用裸蓋菇素類似物克服疾病。該公司通過嚴格的科學和臨床試驗推動藥物開發，同時努力申請專利並保護其知識產權。
For more information and to subscribe to MYND's mailing list, please visit .
欲瞭解更多資訊並訂閱MyND的郵件列表，請訪問。
CONTACT INFORMATION
聯繫資訊
Dr. Lyle Oberg, MD, CEO
Email: ir@myndsciences.com
Web:
Lyle Oberg博士，醫學博士，首席執行官
電子郵件：ir@myndcerences.com
網頁：
Forward-Looking Statements
前瞻性陳述
This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this release.
本新聞稿包含符合適用證券法規的前瞻性陳述和資訊。前瞻性陳述和資訊常常但不總是可以通過使用諸如“計劃”、“預期”或“不預期”、“預期”、“估計”、“打算”、“預期”或“不預期”或“相信”等詞語或這些詞語的變體來識別，或陳述某些行動、事件或結果“可能”、“可能”、“將”、“可能”或“將”被採取、發生或實現。前瞻性陳述或資訊涉及已知和未知的風險、不確定性和其他因素，可能導致MyND的實際結果、業績或成就與本新聞稿中包含的前瞻性陳述或資訊明示或暗示的任何未來結果、業績或成就大不相同。
Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
前瞻性資訊涉及的風險、不確定性和其他因素可能導致實際事件、結果、業績、前景和機會與此類前瞻性資訊明示或暗示的情況大不相同。加拿大證券交易所沒有對本新聞稿內容的充分性或準確性進行審查，也不承擔任何責任。
None of the securities issued in connection with the Offering will be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.
與此次發行相關的任何證券都不會根據修訂後的《1933年美國證券法》(下稱《1933年法案》)進行註冊，而且如果沒有註冊或獲得1933年法案註冊要求的適用豁免，這些證券都不能在美國發行或出售。本新聞稿不應構成出售要約或徵求購買要約，也不應在任何這樣的要約、招攬或出售將是非法的任何州出售證券。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。